Ludovic Doucet

Ludovic Doucet

Auto-generated profile, based on publicly available information

Ludovic Doucet

Department of Medical Oncology, Institute de Cancérologie de l’Ouest, Saint-Herblain, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
OAOlivier Adotévi
Olivier Adotévi
DVDewi Vernerey
Dewi Vernerey
PJPascale Jacoulet
Pascale Jacoulet
AMAurélia Meurisse
Aurélia Meurisse
CLCaroline Laheurte
Caroline Laheurte
VWVirginie Westeel
Virginie Westeel
PURPOSE: Universal cancer peptide–based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase. This phase Ib/IIa trial was designed to test the safety, immunogenicity, and efficacy of a three-dose schedule in patients with metastatic non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with refractory NSCLC were assigned to receive three vaccination doses of UCPVax (0.25 mg, 0.5 mg, and 1 mg) using a Bayesian-based phase Ib followed by phase IIa de-escalating design. The primary end points were dose-limiting toxicity and immune response after three first doses of vaccine. Secondary end points were overall survival (OS) and progression-free survival at 1 year. RESULTS: A total of 59 patients received UCPVax; 95% had three prior lines of systemic therapy. No dose-limiting toxicity was observed in 15 patients treated in phase Ib. The maximum tolerated dose was 1 mg. Fifty-one patients were eligible for phase IIa. The third and sixth dose of UCPVax induced specific CD4+ T helper 1 response in 56% and 87.2% of patients, respectively, with no difference between three dose levels. Twenty-one (39%) patients achieved disease control (stable disease, n = 20; complete response, n = 1). The 1-year OS was 34.1% (95% CI, 23.1 to 50.4), and the median OS was 9.7 months, with no significant difference between dose levels. The 1-year progression-free survival and the median OS were 17.2% (95% CI, 7.8 to 38.3) and 11.6 months (95% CI, 9.7 to 16.7) in immune responders ( P = .015) and 4.5% (95% CI, 0.7 to 30.8) and 5.6 months (95% CI, 2.5 to 10) in nonresponders ( P = .005), respectively. CONCLUSION: UCPVax was highly immunogenic and safe and provide interesting 1-year OS rate in heavily pretreated advanced NSCLC.

10 October 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
MWMengzhao Wang
Mengzhao Wang
LDLudovic Doucet
Ludovic Doucet
YFYun Fan
Yun Fan
DLDongqing Lv
Dongqing Lv
XLXiuning Le
Xiuning Le
PURPOSE: WU-KONG1B (ClinicalTrials.gov identifier: NCT03974022 ) is a multinational phase II, dose-randomized study to assess the antitumor efficacy of sunvozertinib in pretreated patients with advanced non–small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) exon 20 insertion mutations (exon20ins). METHODS: Eligible patients with advanced-stage EGFR exon20ins NSCLC were randomly assigned by 1:1 ratio to receive sunvozertinib 200 mg or 300 mg once daily (200 and 300 mg-rand cohorts). After predefined interim analysis, additional patients were enrolled and treated with the 300 mg dose once daily. The primary end point was blinded independent review committee (IRC)–assessed confirmed objective response rate (cORR), and the key secondary end point was duration of response (DoR). RESULTS: Among 85, 89, and 107 efficacy-evaluable patients in 200 mg-rand, 300 mg-rand, and 300 mg-all (including randomly assigned and nonrandomized patients) cohorts, the cORRs were 45.9% (97.5% CI, 33.6% to 58.5%), 47.2% (97.5% CI, 35.1% to 59.5%), and 45.8% (97.5% CI, 34.8% to 57.0%), respectively, per IRC assessment. The predefined null hypothesis was rejected with statistical significance ( P < .0001). Comparing 300 and 200 mg-rand cohorts, higher cORRs were observed in patients with baseline brain metastasis (52.4% v 28.6%) and previous amivantamab treatment (41.7% v 25%), as well as longer DoR (13.8 v 11.1 months). At 200 and 300 mg once daily, the most common treatment-related adverse events with grade ≥3 included diarrhea (2.2% v 18%), blood creatine phosphokinase increased (6.6% v 12.6%), and anemia (4.4% v 6.3%). CONCLUSION: Sunvozertinib is efficacious at both 200 and 300 mg once daily in treating platinum-pretreated patients with advanced EGFR exon20ins NSCLC. The treatment-related adverse events of sunvozertinib were consistent with an EGFR tyrosine kinase inhibitor, with a more favorable safety profile at 200 mg than 300 mg once daily.

1 August 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
JLJuliette Lemasson
Juliette Lemasson
SCStefania Cuzzubbo
Stefania Cuzzubbo
LDLudovic Doucet
Ludovic Doucet
VGValérie Gounant
Valérie Gounant
BBBarouyr Baroudjian
Barouyr Baroudjian
JDJulie Delyon
Julie Delyon

2 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
VGValérie Gounant
Valérie Gounant
MDMichael Duruisseaux
Michael Duruisseaux
Ghassen SoussiGhassen Soussi
Ghassen Soussi
SHSylvie Van Hulst
Sylvie Van Hulst
OBOlivier Bylicki
Olivier Bylicki
GZGérard Zalcman
Gérard Zalcman
Anti-PD-1 antibodies prolong survival of performance status (PS) 0–1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3–4 patients is unknown. Conse- cutive PS 3–4 aNSCLC patients receiving compassionate nivolumab were accrued by 12 French thoracic oncology departments, over 24 months. Overall survival (OS) was calculated using the Kaplan-Meier method. Prognostic variables were assessed using Cox proportional hazards models. Overall, 35 PS 3–4 aNSCLC patients (median age 65 years) received a median of 4 nivolumab infusions (interquartile range [IQR], 1–7) as first- (n = 6) or second-line (n = 29) therapy. At a median of 52-month follow-up (95%CI, 41–63), 32 (91%) patients had died. Median progression-free survival was 2.1 months (95%CI, 1.1–3.2). Median OS was 4.4 months (95%CI, 0.5–8.2). Overall, 20% of patients were alive at 1 year, and 14% at 2 years. Treatment-related adverse events occurred in 8/35 patients (23%), mostly of low-grade. After adjustment, brain metastases (HR = 5.2; 95%CI, 9–14.3, p = 0.001) and <20 pack-years (HR = 4.8; 95%CI, 1.7–13.8, p = 0.003) predicted worse survival. PS improvement from 3–4 to 0–1 (n = 9) led to a median 43-month (95%CI, 0–102) OS. Certain patients with very poor general condition could derive long-term benefit from nivolumab salvage therapy.

1 April 2019 in Lung Cancer
Verified
Journal Article
Closed access
ACAdrien Costantini
Adrien Costantini
VFV. Fallet
V. Fallet
JCJ. Corny
J. Corny
SFS. Friard
S. Friard
CCchristos chouaid
christos chouaid
JCJacques Cadranel
Jacques Cadranel

17 September 2024 in Annals of Oncology
Verified
Journal Article
Closed access
FBF. Barlesi
F. Barlesi
WYW. Yao
W. Yao
MDM. Duruisseaux
M. Duruisseaux
LDL. Doucet
L. Doucet
JSJ. Shi
J. Shi
TMT.S.K. Mok
T.S.K. Mok